BACKGROUND AND OBJECTIVES
The prediction of pathological response outcome following neoadjuvant chemotherapy (NAC) in breast cancer is an important clinical task that aids treatment planning and personalized therapeutic strategies. Traditional prediction strategies require expert knowledge and are sometimes influenced by False Positive and False Negative outcomes.
METHODS
In this study, we propose a new multi-modal machine learning framework that combines the structural, textural and functional imaging biomarkers obtained from Dynamic Contrast-Enhanced MRI (DCE-MRI) for non-invasive classification of complete response (CR) and partial response (PR). The clinical dataset used in our study was collected at Annunziata Hospital, Cosenza, Italy (33 breast cancer patients total with confirmed response labels). The method investigates three complementary feature spaces: (i) quantitative perfusion and geometry parameters obtained from time-intensity curves capturing tumor vascular dynamics, (ii) radiomic features encoding intra-tumoral structural and textural heterogeneity, and finally (iii) a modal-aware late fusion using a Bayesian meta-learner integrating both descriptors.
RESULTS
To prevent overfitting on medical imaging datasets, a stringent validation approach based on Nested Leave-One-Out Cross-Validation (Nested LOOCV) in conjunction with repeated Stratified 5 × 20 cross-validation was implemented. Accuracy was as high as 0.8955 with perfusion-based models, and a radiomic model yielded an accuracy score of 0.8982 using Mann-Whitney feature selection under Nested LOOCV. Overall, the multi-modal fusion approach achieved superior performance (0.9115 accuracy, 0.9054 F1-score, and 0.9488 ROC-AUC) using Random Forest classifier, which indicates that combining perfusion dynamics with radiomics enables a more clinically-relevant prediction of NAC response.
CONCLUSIONS
This shows that the combination of perfusion dynamics with radiomic descriptors from DCE-MRI allows for better and more reliable prediction of NAC response. This proposed multimodal framework also emphasizes the promising role of imaging biomarkers in facilitating tailored treatment approaches for breast cancer.
Yasser Radouane Haddadi, Ruhul Amin Hazarika, Asaf Raza et al.· Computer Methods and Program...· 0 citations
Querying clinical trial registries remains a manual and error-prone process, requiring researchers to navigate large volumes of semi-structured data without support for natural language interaction or cross-source synthesis. To address this, we introduce ClinAgent, a conversational system based on agentic Retrieval-Augmented Generation (RAG) that enables clinicians and researchers to query clinical trial information in plain language and receive grounded, up-to-date responses across multi-turn interactions. The system centers on a Large Language Model (LLM) agent following the ReAct paradigm, which iteratively reasons over queries, selects among a set of integrated tools, and refines its actions based on intermediate outputs. These tools include a ClinicalTrials.gov search interface, a PubMed module, and a Python-based analyzer operating on a locally cached structured dataset of clinical trials. We evaluate the system using a three-phase framework assessing operational effectiveness, planning quality, tool-use efficiency, and expert qualitative judgments, comparing three LLM backends: Gemini 3.0 Flash and two variants of DeepSeek V3.2 (thinking and non-thinking). Results reveal complementary strengths, with DeepSeek (thinking mode) excelling in planning quality, while Gemini achieves the highest overall performance and strongest expert ratings. Overall, our findings highlight the potential of agentic AI systems to improve the accessibility and synthesis of clinical trial information, supporting more efficient and user-centered biomedical research workflows.
Antonino Vaccarella, Riccardo Cantini, Domenico Talia et al.· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.